INS and hereditary sensory and autonomic neuropathy: In the CIP group, 6.5% of patients were managed with lifestyle measures only, 45.2% with oral antidiabetic drugs (OADs), 16.1% with insulin, and 32.3% with a combination of OADs and insulin.